Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Rimonabant restricted by NICE

The National Institute for Health and Clinical Excellence (NICE) has issued guidance (PDF) for using rimonabant (Acomplia®) for the treatment of obesity.

The guidance allows the use of rimonabant but only in patients for whom orlistat and sibutramine has proved inadequate, been poorly tolerated or is contraindicated. The guidance further qualifies that steatorrhoea associated with orlistat when not adhering to dietary advice is not considered as intolerance.

Action: NICE has clearly placed rimonabant as the third line treatment for obesity after orlistat and sibutramine. Clinicians should ensure that treatment of obesity reflects this advice.

Share 'Rimonabant restricted by NICE' on Email Share 'Rimonabant restricted by NICE' on Delicious Share 'Rimonabant restricted by NICE' on Digg Share 'Rimonabant restricted by NICE' on Facebook Share 'Rimonabant restricted by NICE' on Google+ Share 'Rimonabant restricted by NICE' on reddit Share 'Rimonabant restricted by NICE' on StumbleUpon Share 'Rimonabant restricted by NICE' on Twitter

atomic-wealth

No Comments to “Rimonabant restricted by NICE”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,658 spam comments.

atomic-wealth
fond-illness
summer